8 I et fase I bioækvivalens- studie hos 72 postmenopausale kvinder, som fik 150 mg oralt hver 28. dag, i ialt 4 doser, blev der set hæmning af CTX efter første dosis allerede 24 timer efter indtagelsen (median hæmning 28%) med median maksimal hæmning (69%) 6 dage senere.
In a Phase 1 bioequivalence study conducted in 72 postmenopausal women receiving 150 mg orally every 28 days for a total of four doses, inhibition in serum CTX following the first dose was seen as early as 24 hours post-dose (median inhibition 28%), with median maximal inhibition (69%) seen 6 days later.